Cerus (NASDAQ:CERS) Announces Earnings Results, Hits Estimates

Cerus (NASDAQ:CERS) issued its earnings results on Monday. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01), FiscalAI reports. The business had revenue of $64.58 million for the quarter, compared to analysts’ expectations of $59.31 million. Cerus had a negative return on equity of 27.58% and a negative net margin of 8.01%.

Here are the key takeaways from Cerus’ conference call:

• Cerus reported record product revenue in 2025 with total revenues of $233.8M (up 16% year-over-year) and reaffirmed 2026 product revenue guidance of $224–$228M, implying ~9–11% product revenue growth.
• Commercial momentum is broad-based — the U.S. platelet franchise remains the core (estimated mid-60s market share), IFC demand surged (volume +110% YoY) and the new BCA group purchasing agreement gives access to ~50% of U.S. blood supply to drive further adoption; the INT200 illuminator has CE mark approval with positive customer feedback and a planned PMA submission in mid-2026.
• Progress on the red blood cell program continues — TÜV SÜD has completed its review and the dossier is moving to ANSM (potential EU approval in H1 2027 if reviews go smoothly), while U.S. RedeS Phase 3 enrollment is complete with top-line results expected in Q4 2026.
• Product gross margin compressed to 51.5% in Q4 (from 53.9% a year earlier) due to higher IFC production costs, import tariffs and inflationary pressures, and management warns tariff uncertainty could continue to pressure 2026 margins.
• Profitability and liquidity improved — seven consecutive quarters of positive non‑GAAP adjusted EBITDA (full-year adjusted EBITDA $9.5M), a reduced GAAP net loss of $15.6M, and about $83M in cash and short-term investments at year-end 2025.

Cerus Price Performance

NASDAQ:CERS traded down $0.03 during mid-day trading on Monday, hitting $2.53. The company’s stock had a trading volume of 1,726,102 shares, compared to its average volume of 1,403,878. The company has a market capitalization of $485.99 million, a price-to-earnings ratio of -31.63 and a beta of 1.51. The company has a current ratio of 1.89, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. Cerus has a fifty-two week low of $1.12 and a fifty-two week high of $2.95. The stock has a fifty day moving average of $2.30 and a 200-day moving average of $1.82.

Wall Street Analyst Weigh In

A number of research analysts have commented on CERS shares. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Institutional Investors Weigh In On Cerus

A number of hedge funds have recently made changes to their positions in CERS. Cibc World Markets Corp bought a new position in Cerus in the 4th quarter worth approximately $25,000. CIBC Bancorp USA Inc. bought a new position in Cerus in the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus in the 1st quarter valued at $32,000. Aquatic Capital Management LLC bought a new stake in shares of Cerus during the third quarter worth $35,000. Finally, MML Investors Services LLC acquired a new position in shares of Cerus during the fourth quarter valued at $37,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.